Kiniksa Pharmaceuticals International, plc
KNSA
$93.90+0.36 (0.38%)Nov 20
After-hours: $95.05 (+1.22%)
Kiniksa Pharmaceuticals International, plc (KNSA)
$93.90+0.36+0.38%Nov 20
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
YTD128%
M.cap.7.4 bn
Std.Dev, 1y2.00
Vol, bn0.1 (med)
RSI55
P/E67.5
MFI53
P/S7.32
ADX18 (no trend)
P/B10.39
Beta0.11
Div—
Debt/EBITDA0.11
Payout—
Price target
Buy 8 (100%)Hold 0 (0%)Sell 0 (0%)
Next earnings—
Earnings surprise
Short interest10.6% (+1.2%), 30 Oct 2026
Fund owners #1 (-1)
Insider ownership$9,004 mm
Insider sellingVery High
Insider buying—
General
M.Cap$7.4B
Dividends—
Next report—
Forecast
Valuation
Target
P/E67.5
P/S7.32
P/B10.39
Fundamentals
5-y avg sales growth+0.0%
Debt / EBITDA0.11
ROE10.4%
Altman Z-score10.35 (safe)
Technicals
RSI55
MFI53
Price / MA50+11.9% (high) ↓
Trend pattern
Financial Statements
No data available
Financial Statements
No data available
Team
Loading…
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Investor Presentations
Loading…
Options
Exp. from:to:
Strike from:to:
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
Stress Test
Loading…
About

Kiniksa Pharmaceuticals is a biopharmaceutical company that seeks to develop and market therapeutic medicines for patients who suffer from severe, unmet medical conditions globally. The company has several product candidates in its pipeline, including ARCALYST, Mavrilimumab, Vixarelimab, and KPL-404, which are in different clinical trial phases. The company was founded in 2015 and is headquartered in Hamilton, Bermuda.

Headcount: 366
Address:105 Piccadilly, London, United Kingdom, W1J 7NJ
About

Kiniksa Pharmaceuticals is a biopharmaceutical company that seeks to develop and market therapeutic medicines for patients who suffer from severe, unmet medical conditions globally. The company has several product candidates in its pipeline, including ARCALYST, Mavrilimumab, Vixarelimab, and KPL-404, which are in different clinical trial phases. The company was founded in 2015 and is headquartered in Hamilton, Bermuda.

https://www.kiniksa.com
Beta 0.11